US FDA approves Mirum drug for rare bone disorder

• Atebrioz works by blocking ALK2, a protein that is abnormally active in most FOP patients and drives bone formation outside the skeleton, with a recommended dose of 100 milligrams
• Mirum plans to launch the drug in October and will announce pricing at that time, according to CEO Chris Peetz
• FOP is a rare genetic disorder that progressively restricts movement and causes severe disability as bone forms in soft tissues throughout the body

US FDA Approves Mirum's Zilurgisertib for Rare Bone Disorder

The US Food and Drug Administration approved Mirum Pharmaceuticals' drug zilurgisertib (branded as Atebrioz) on Friday, September 25, marking the first treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic bone disorder.

Key Product Details:

Atebrioz is a once-daily oral treatment approved for patients aged 12 years and older with FOP. The recommended dose is 100 milligrams. The drug works by blocking ALK2, a protein abnormally active in most FOP patients that drives abnormal bone formation in muscles, tendons, and ligaments outside the skeleton.

Disease Background:

FOP is a rare genetic disorder causing bone to form in soft tissues, progressively restricting movement and leading to severe disability. This approval addresses a significant unmet medical need for patients with this debilitating condition.

Launch Timeline:

Mirum CEO Chris Peetz announced the company expects to launch Atebrioz in October. Pricing details will be disclosed at launch, though no specific amount has been provided yet.

Market Implications:

This approval represents a significant milestone for Mirum Pharmaceuticals, providing the company entry into the rare disease treatment market. As an orphan drug for an ultra-rare condition, Atebrioz will likely command premium pricing and benefit from regulatory exclusivity periods. The October launch timeline suggests immediate revenue potential for the company in Q4. Investors in the rare disease pharmaceutical sector should monitor the pricing announcement and initial uptake closely, as it could establish benchmarks for similar ultra-rare disease treatments.